Betekenis van:
omega-3

omega-3
Zelfstandig naamwoord
    • a polyunsaturated fatty acid whose carbon chain has its first double valence bond three carbons from the beginning

    Synoniemen

    Hyperoniemen

    Hyponiemen


    Voorbeeldzinnen

    1. Poly(oxy-1,2-ethanediyl), .alpha.-(3-carboxy-1-oxo-3-sulfopropyl)-.omega.-(dodecyloxy)-, disodium salt
    2. Poly(oxy-1,2-ethanediyl), .alpha.-hexadecyl-.omega.-hydroxy- (3 mol EO average molar ratio)
    3. C14-15-alkyl-, .omega. 2-hydroxy-3-sulfopropyloxy, sodium salt Cleansing/surfactant
    4. Poly(oxy-1,2-ethanediyl), .alpha.-sulfo-.omega.-(octyloxy)-, ammonium salt (3 mol EO average molar ratio)
    5. Poly(oxy-1,2-ethanediyl), .alpha.-(3-carboxy-1-oxo-2(or 3)-sulfopropyl)-.omega.-(nonylphenyl)-, disodium salt
    6. Poly(oxy-1,2-ethanediyl), .alpha.-(3-carboxy-1-oxosulfopropyl)-.omega.-hydroxy-, ethers with lanolin alcs., disodium salts
    7. Bis-(2-hydroxyethyl)ammonium poly(oxy-1,2-ethanediyl)-.alpha.-(C12-13)-alkyl-.omega.-sulfate, (3 mol EO average molar ratio)
    8. Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy-, ether with methyl .beta.-d-glucopyranoside (4:1), octadecanoate (2:3)
    9. Today, in the foods of the categories for which the addition of oil from the micro-algae Ulkenia sp. was requested omega-3 fatty acids can be provided either from fish oil or alternatively from the micro algae Ulkenia sp.
    10. Following two applications from Pharma Consulting & Industries submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the calming effect of I omega kids®/Pufan 3 kids® (Question No EFSA-Q-2008-091 and – Question No EFSA-Q-2008-096) [16].
    11. Following two applications from Pharma Consulting & Industries submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of I omega kids®/Pufan 3 kids® on learning ability (Question No EFSA-Q-2008-102 and Question No EFSA-Q-2008-103) [22].
    12. Following two applications from Pharma Consulting & Industries submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of I omega kids®/Pufan 3 kids® on thinking capacity (Question No EFSA-Q-2008-093 and Question No EFSA-Q-2008-101) [21].
    13. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised. (47) Following two applications from Pharma Consulting & Industries submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of I omega kids®/Pufan 3 kids® on thinking capacity (Question No EFSA-Q-2008-093 and Question No EFSA-Q-2008-101) [21].
    14. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised. (37) Following two applications from Pharma Consulting & Industries submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the calming effect of I omega kids®/Pufan 3 kids® (Question No EFSA-Q-2008-091 and – Question No EFSA-Q-2008-096) [16].
    15. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised. (45) Following two applications from Pharma Consulting & Industries submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related the effects of I omega kids®/Pufan 3 kids® on concentration (Question No EFSA-Q-2008-094 and Question No EFSA-Q-2008-099) [20].